Idiopathic Pulmonary Fibrosis Market Updates

Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to idiopathic pulmonary fibrosis market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.

Idiopathic Pulmonary Fibrosis Market News

  • Plans to file a new drug application for the treatment of IPF were prompted by an announcement that Boehringer Ingelheim issued on September 2024 stating that nerandomilast FIBRONEER-IPF trial achieved its primary objective. 
  • Options for Indications of Idiopathic and Progressive Pulmonary Fibrosis, Ferrer extended the exclusive licensing agreement in May 2024 with United Therapeutics to acquire worldwide rights of treprostinil inhalation solution. 
  • Daewoong Pharmaceutical and CS Pharmaceuticals agreed on the license for the first-in-class PRS inhibitor Bersiporocin to be distributed in Greater China in January 2023. It involves mainland China, Hong Kong, Taiwan, and Macau. For the aggregate amount up to USD 336m consisting of the sum of up to USD 76m in milestone payments due upon the achievement of specified development milestones, plus double-digit royalties on net sales, CSP shall license in bersiporocin for IPF and for other fibrotic conditions.
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Idiopathic Pulmonary Fibrosis Market size was valued at USD 4.02 Billion in 2023 and is poised to grow from USD 4.3 Billion in 2024 to USD 11.55 Billion by 2032, growing at a CAGR of 6.98% during the forecast period (2025-2032).

United Therapeutics Corporation ', 'Boehringer Ingelheim International GmbH ', 'Bristol-Myers Squibb Company ', 'Cipla Inc. ', 'F. Hoffmann-La Roche Ltd ', 'FibroGen Inc. ', 'MediciNova Inc. ', 'Jubilant Pharma Limited (Jubilant Cadista Limited) ', 'Merck & Co. Inc. ', 'Horizon Therapeutics Inc. ', 'Avalyn Pharma Inc. ', 'AstraZeneca ', 'Novartis AG ', 'GlaxoSmithKline plc ', 'Genentech, Inc. ', 'Biogen Inc. ', 'Pfizer Inc. ', 'AbbVie Inc. ', 'Bayer AG ', 'Amgen Inc.

The prevalence of idiopathic pulmonary fibrosis is rising due to the growing age of the population and increasing environmental factors that include and more than which is air pollution and occupational exposures.

One of the major idiopathic pulmonary fibrosis market trends includes personalization of medicines.

As per the idiopathic pulmonary fibrosis market forecast, North America dominated the market with 37.5% revenues in 2024.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Idiopathic Pulmonary Fibrosis Treatment Market
Buy Now GET FREE SAMPLE
Pulmonary Arterial Hypertension Market
Buy Now GET FREE SAMPLE
Cystic Fibrosis Therapeutics Market
Buy Now GET FREE SAMPLE
Lung Cancer Market
Buy Now GET FREE SAMPLE
Non-Small Cell Lung Cancer Market
Buy Now GET FREE SAMPLE
Lung Cancer Surgery Market
Buy Now GET FREE SAMPLE
Lung Cancer Therapeutics Market
Buy Now GET FREE SAMPLE
Atrial Fibrillation Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Idiopathic Pulmonary Fibrosis Market
Idiopathic Pulmonary Fibrosis Market

Report ID: SQMIG35H2223

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE